In January 2024, the Office of Compliance at the FDA’s Center for Drug Evaluation Research (CDER) released its Annual Report for FY2023. The Annual Report contains several useful pieces.
DGAP-News: Biotest AG / Key word(s): Study02.06.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest successfully completes recruitment for its clinical trial with trimodulin in severe COVID-19 patients - Trimodulin as potential life-saving treatment for severe COVI.